Cell‐specific delivery of the drugs to their corresponding target cells is crucial, as chemotherapeutic agents may inadvertently harm immune cells, compromising their biological functions, albeit inducing immunogenic cell death (ICD) of cancer cells.[11] IL15 and serum soluble IL15Rα bound IL15 would lead to tumor progression via promoting cancer cell proliferation and migration and inducing systemic inflammation cytokines, respectively.[12] To overcome these challenges, a meticulously tailored combination therapy approach is required. The gene discussed is IL15RA; the disease is neoplasm.